Device Trial Radar · NCT06260670
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Sep 1, 2022
Primary completion
Oct 28, 2022
Study completion Oct 28, 2022
Sponsor
- Lead sponsor
- Ablacon, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 15, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FLOW EVAL-AF is a prospective, observational, single center pilot trial. The FLOW EVAL-AF trial is designed to identify driver sources in patients with persistent or longstanding persistent AF using EGF mapping and describe the activation patterns observed from concomitant high density mapping of those regions.
Conditions
- Persistent Atrial Fibrillation
- Longstanding Persistent Atrial Fibrillation
- Atrial Fibrillation, Persistent
- Arrhythmias, Cardiac
Interventions
Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ CatheterDevice
Subjects will receive ElectroGraphic Flow™ (EGF) mapping with Ablamap® Software and a commercially available 64-pole basket mapping catheter (FIRMap™ Catheter, Abbott Laboratories, Abbott park, IL). The FIRMap™ catheter will be inserted into the right and left atrium to acquire 1 minute recordings of electrical signals in several standardized positions, and turn these into electrographic flow (EGF) maps. Subjects will receive concomitant high density (HD) electroanatomical mapping of these regions with the commercially available Ensite Precision mapping system and Advisor™ HD Grid mapping catheter (Abbott Laboratories, Abbott Park, IL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Successful Acquisition of EGF Mapping and High Density MappingTime frame: Intraprocedural
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Herz-und Diabeteszentrum NRW (Clinic of Ruhr University of Bochum)
Bad Oeynhausen, North Rhine-Westphalia, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.